#Viekira Pak

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

In a recent British Columbia study, 1 in 10 people who began treatment were lost to follow-up.

The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

This is according to an analysis of a large group of veterans.

More than 125,000 veterans will have received lifesaving cures by October 2018.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

These include a low CD4 count, having cirrhosis and taking certain hep C drug regimens.

Human rights activist Philip Baldwin writes about his experiences living with hepatitis C and HIV, and his treatment for hep C.

Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.

A large study shows that hepatitis C treatment is associated with increased mortality.

A promising new regimen that will address unmet needs for this population is poised for FDA approval.

Those who beat hep C also reduced their insulin use.

The triple-drug regimen comes in a once-daily single tablet.

A recent economic analysis sheds light on whether averting hep C–driven severe liver disease through treatment is worth the expense.

The antiviral drug, which for some people can be a beneficial adjunct to the new crop of hep C medications, has gotten a bad rap.

Part 2 of Connie Welch’s interview with a hep C patient sharing her experience with hepatitis C treatment.